Navigation Links
NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria
Date:11/30/2007

HELSINGBORG, Sweden, November 30 /PRNewswire/ -- NOLabs AB, the Swedish medtech company developing innovative nitric oxide-containing medical devices based on the NitroSense(R) Technology, today reported that it has achieved another important milestone in the development of a new line of products for wounds infected by MRSA-bacteria. MRSA stands for Methicillin Resistant Staphylococcus aureus, a bacterium that is particularly troublesome in hospital-acquired infections due to its resistance to several traditional antibiotics.

In experiments performed at the Malmoe University Hospital in Sweden, researchers showed that NOLabs' technology has a promising ability to kill a wide range of pathogens, including MRSA.

According to the US Centers for Disease Control and Prevention 126,000 hospitalisations are related to MRSA and 19,000 deaths are associated with serious MRSA infections every year in U.S. hospitals. Patients at risk for infection with MRSA include those with severe disease, recent surgery or indwelling medical devices, such as urinary catheters.

Goran Beijer, CEO of NOLabs says: "The recent results show that we are on the right track towards products with an enormous potential globally. The anti-microbial effect of NO will be key in several products that will prevent and/or treat infection depending on dosing. We are now accelerating our development program and expect to have the first products on the market during 2008."

NOLabs' NitroSense(R) Technology assures controlled, local delivery of pure nitric oxide in a well-defined concentration range during a well-defined time period. The main areas are prevention of catheter related urinary tract infections, relief of neuropathic pain and wound care products with an anti-bacterial effect.

For more information please visit our home page: http://www.nolabs.com

NOLabs is a Swedish medtech company developing and marketing nitric oxide-containing medical devices for various medical applications. Nitric oxide is a natural substance, produced by the human body. Its physiological effects include the control of local blood supply and the protection against microbes. In particular, NOLabs focuses on prevention of infection and pain relief for patients suffering from diabetes-related complications such as chronic wounds and neuropathic pain. Another focus area is the prevention and treatment of catheter-associated urinary tract infections. NOLabs has developed the innovative, cost efficient and highly effective NitroSense(R) Technology with a significant potential to address serious health issues that impact the lives of over 100 million people.

Goran Beijer,

E-mail goran.beijer@nolabs.com,

Phone: +46-42-33-65-22;

Susanne Goransson,

E-mail: susanne.goransson@nolabs.com,

Phone: +46-42-33-65-30.


'/>"/>
SOURCE NOLabs AB
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Pharsight Achieves First License Sale for Public-Source Database
2. GenoLogics Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform
3. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
4. Signalife Achieves $1.98 Million Sales Orders Thus Far
5. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
6. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
7. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
8. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
9. Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
10. Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against Superbugs
11. Soap and Water May not be Enough to Fight MRSA Superbug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... CNA Finance Chief ... provided a research update on Aytu Bioscience and cited promising increases in the ... Soulstring, prescription rates for Natesto® have more than doubled since March of this ...
(Date:8/16/2017)... ... ... While art and science are often thought of as two completely separate ... A Mesh Is Also a Snare, a group exhibition presented by the Philadelphia-based artist ... (EKG) on August 17 and run through September 30. An opening reception will be ...
(Date:8/15/2017)... STANFORD, Calif. , Aug. 15, 2017 After spending ... resources and support with crowdsourced data collection, GeneFo now offers this ... interested in aligning and amplifying support, adherence, and data collection vis ... with medical foundations mark the successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... Kenosha, Wisconsin (PRWEB) , ... August 15, 2017 ... ... introduced a new family of 6” modular downlights designed to stay tightly sealed ... applications, including areas where damp and wet location listings just aren't enough, such ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
Breaking Biology News(10 mins):